Moderna, Inc. remains under pressure in 2025, despite recent next-gen COVID vaccine approval & cancer vaccine trial. Learn ...

UEFA Technical Observer Joe Montemurro highlights Manchester United's defensive mettle in their Matchday 2 victory over ...

With world leaders set to gather in Brazil for COP30 in November, new analysis from an international team of climate policy ...

The Bitcoin price has dropped by 5.13% in the past 24 hours to trade at $105,217.60, extending its recent correction. This ...

After 5 years, Kisqali® plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive disease-free survival1 Kisqali remains the only CDK4/6 inhibitor ...

Advances in mass spectrometry and chromatography are enhancing pesticide residue analysis, focusing on exposomics and risk assessment for improved food safety. Ion chromatography is evolving with new ...

The Gaza ceasefire agreement was mediated by the United States along with Egypt, Qatar and Turkey. Its second phase calls for ...

Combining the PARP1-selective inhibitor saruparib with an androgen receptor pathway inhibitor (ARPI) demonstrated promising efficacy and safety in patients with metastatic prostate cancer, according ...

Imfinzi plus FLOT chemotherapy significantly improves overall survival in resectable G/GEJ adenocarcinoma compared to placebo ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein ...

Eli Lilly and Company today announced results from the primary overall survival (OS) analysis of the Phase 3 monarchE trial ...

The Big Pharma’s window to take up exclusive rights to Taysha’s lead asset, dubbed TSHA-102, has officially closed, according ...